share_log

Tilray Remains a Solid Pot Play

Tilray Remains a Solid Pot Play

Tilray仍然是一個可靠的博彩遊戲
InvestorPlace ·  2021/11/22 15:16

InvestorPlace - Stock Market News, Stock Advice & Trading Tips

InvestorPlace-股市新聞、股票諮詢和交易提示

Tilray (NASDAQ:TLRY) stock has climbed since October, but it remains far below its past highs. After the Democratic Party's "blue wave" in last year's U.S. elections failed to result in  legalization, the retreat of Canada-based cannabis plays like TLRY stock makes sense.

Tilray(納斯達克:TLRY)股價自去年10月以來一直在攀升,但仍遠低於過去的高點。在民主黨在去年美國大選中的“藍色浪潮”未能導致大麻合法化後,加拿大大麻的撤退就像TLRY股票一樣有意義。

Pot is now legal in dozens of U.S. states. But without changes in federal law, Canadian names like Tilray  can't enter  the U.S., which could become the  world's largest legal cannabis market. Before diving back into Tilray, Canopy Growth (NASDAQ:CGC), and others, investors are waiting for Congress to legalize marijuana.

大麻現在美國幾十個州都是合法的。但如果不修改聯邦法律,像Tilray這樣的加拿大名字就不能進入美國,美國可能成為世界上最大的合法大麻市場。在潛入Tilray之前,冠層生長納斯達克(Sequoia Capital:CGC)和其他公司的投資者正在等待國會將大麻合法化。

Consequently, TLRY stock and its peers could continue to deliver mediocre returns in the near-term. Yet this "out of favor" status for the sector among Main Street and Wall Street investors may provide investors with a good opportunity. Despite doubts about whether U.S. legalization will ever occur, there's a good chance that the drug will be legalized in a few short years.

因此,TLRY股票及其同行可能在短期內繼續提供平庸的回報。然而,該行業在普通民眾和華爾街投資者中的這種“失寵”狀態可能會為投資者提供一個很好的機會。儘管對美國是否會合法化存在疑問,但這種藥物很有可能在短短几年內合法化。

Further, Tilray has some other possible, positive catalysts on the table. Although the shares may not rally for some time, you may want to take a bullish position in the name, since its share price is likely to undergo  an epic rebound.

此外,Tilray還有其他一些可能的、積極的催化劑擺在桌面上。雖然股價可能在一段時間內不會反彈,但你可能希望在名義上持看漲立場,因為它的股價很可能經歷Epic的反彈。

Recent Pot Legalization News

最近的大麻合法化新聞

Oddly enough, the most recent push for reform has come not from the Democrats, but from a Republican.

奇怪的是,最近推動改革的不是民主黨人,而是共和黨人。

On Nov 16, Rep. Nancy Mace (R-SC) introduced a marijuana decriminalization bill. The bill would eliminate all  federal restrictions on the drug. At the same time, it would enable states to decide whether to legalize it.

11月16日,眾議員南希·梅斯(R-SC)提出了一項大麻非刑事化法案。該法案將取消聯邦政府對該藥物的所有限制。與此同時,它將使各州能夠決定是否將其合法化。

This bill alone doesn't signal that the Republicans are about to become as pro-pot as the Democrats. After all, the Republican Party in Mace's home state of South Carolina has expressed its opposition to her bill. But Mace's bill bolsters the argument that legalization is becoming more of a bipartisan issue. So no matter which party controls Congress after the 2022 midterm elections, marijuana reform is still just around the corner.

僅憑這項法案並不能表明共和黨人即將變得像民主黨人一樣支持大麻。畢竟,梅斯的家鄉南卡羅來納州的共和黨已經表達了對她的法案的反對。但梅斯的法案支持了合法化越來越成為兩黨問題的論點。因此,無論哪個政黨在2022年中期選舉後控制國會,大麻改革仍指日可待。

  • 7 Stocks to Watch Now as Consumer Prices Spike

  • 消費者價格飆升,現在值得關注的7只股票

As  Tilray CEO Irwin Simon has said, legalization is far from a silver bullet when it comes to solving this company's problems. Even if Congress legalizes the drug soon, Tilray's financial results would not improve  tremendously for some time.

正如Tilray首席執行官歐文·西蒙所説,要解決這家公司的問題,合法化遠非靈丹妙藥。即使國會很快將該藥物合法化,Tilray的財務業績在一段時間內也不會有太大改善。

That said, progress towards legalization would cause a spike in its stock price. After the electric vehicle (EV) and related stocks went up following Congress' passing of the infrastructure bill, popular pot stocks could embark on a similar rally if lawmakers  moves towards legalizing the drug.

也就是説,合法化的進展將導致其股價飆升。在國會通過基礎設施法案後,電動汽車(EV)和相關股票上漲後,如果立法者朝着毒品合法化邁進,受歡迎的大麻類股可能會出現類似的漲勢。

Other Possible Catalysts Could Lift the Shares

其他可能的催化劑可能會提振股價

Tilray's  potential gains from pot reform may outweigh its possible drops. But among the Canada-based cannabis stocks, names like Sundial Growers (NASDAQ:SNDL) may be better ways to wager on this catalyst. With Sundial's low stock price, it could spike more dramatically than Tilray on progress towards  U.S. legalization.

Tilray從大麻改革中獲得的潛在收益可能會超過其可能的跌幅。但在加拿大的大麻庫存中,像這樣的名字日規種植者納斯達克(Sequoia Capital:SNDL)可能是押注於這一催化劑的更好方式。由於Sunial的股價較低,在美國合法化的進展方面,它可能會比Tilray更戲劇性地飆升。

However, there's more on Tilray's side than just the prospect of it entering the American pot market within a few years. Other catalysts could help  its stock price rebound.

然而,Tilray的方面不僅僅是它在幾年內進入美國大麻市場的前景。其他催化劑可能有助於其股價反彈。

I discussed two of these catalysts when I last wrote about TLRY stock last month. First, the company plans to grow its share of the high-margin medical pot market in Canada and Europe. Second,  its strategy to buy  other pot companies could enable it to save money.

上個月我在寫關於TLRY股票的文章時討論了其中的兩個催化劑。首先,該公司計劃擴大其在加拿大和歐洲高利潤率醫用大麻市場的份額。其次,它收購其他大麻公司的戰略可以讓它省錢。

On top of this, the company could grow its exposure to the U.S. pot market while reforms are pending. It could do so  by making more deals similar  to the one it concluded with MedMen Enterprises (OTCMKTS:MMNFF) earlier this year. This complex transaction, which involved the use of convertible securities and warrants, gave it an economic interest in the U.S.-based pot purveyor.

最重要的是,在改革懸而未決的同時,該公司可能會增加對美國大麻市場的敞口。它可以通過達成更多類似於它與之達成的交易來做到這一點。梅德曼企業(OTCMKTS:MMNFF)今年早些時候。這筆複雜的交易涉及使用可轉換證券和認股權證,使其在這家美國大麻供應商中獲得了經濟利益。

The Bottom Line on TLRY Stock

TLRY股票的底線

It's understandable why Tilray and its peers are still out of favor. But that doesn't mean that the name will continue to underwhelm investors. The shares could spike on any legalization news. Or other parts of its game plan could become successful, enabling its share price to start rebounding.

Tilray和它的同行仍然失寵,這是可以理解的。但這並不意味着這個名字將繼續讓投資者印象不佳。任何合法化消息都可能導致該公司股價飆升。或者,它的遊戲計劃的其他部分可能會變得成功,使其股價開始反彈。

With TLRY stock already beaten down, a shift in investors' sentiment could enable it to pop tremendously  down the road. Before that happens,  bottom fishers may want to buy it.

由於TLRY的股票已經受到重創,投資者情緒的轉變可能會使它在未來大幅上漲。在此之前,底層捕魚者可能會想買下它。

On the date of publication, Thomas Niel did not have (either directly or indirectly) any positions in the securities mentioned in this article. The opinions expressed in this article are those of the writer, subject to the InvestorPlace.com Publishing Guidelines.

在出版之日,託馬斯·尼爾沒有(直接或間接)持有本文所述證券的任何頭寸。本文中表達的觀點是作者的觀點,受InvestorPlace.com發佈指南的約束。

Thomas Niel, a contributor for InvestorPlace.com, has been writing single-stock analysis for web-based publications since 2016.

託馬斯·尼爾(Thomas Niel),InvestorPlace.com,自2016年以來一直在為基於網絡的出版物撰寫單一股票分析。

The post Tilray Remains a Solid Pot Play appeared first on InvestorPlace.

帖子Tilray仍然是一個堅實的Pot Play最先出現在InvestorPlace上。

声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息
    搶先評論